Cencora, Inc. (COR)
NYSE: COR · Real-Time Price · USD
338.87
0.00 (0.00%)
Jan 2, 2026, 4:00 PM EST - Market open
Cencora Market Cap
Cencora has a market cap or net worth of $65.74 billion as of January 5, 2026. Its market cap has increased by 47.99% in one year.
Market Cap
65.74B
Enterprise Value
70.71B
1-Year Change
47.99%
Ranking
Category
Stock Price
$338.87
Market Cap Chart
Since December 1, 1998, Cencora's market cap has increased from $1.54B to $65.74B, an increase of 4,176.23%. That is a compound annual growth rate of 14.86%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 2, 2026 | 65.74B | 0.33% |
| Dec 31, 2025 | 65.52B | 50.88% |
| Dec 31, 2024 | 43.43B | 5.35% |
| Dec 29, 2023 | 41.22B | 20.95% |
| Dec 30, 2022 | 34.08B | 23.22% |
| Dec 31, 2021 | 27.66B | 38.52% |
| Dec 31, 2020 | 19.97B | 14.05% |
| Dec 31, 2019 | 17.51B | 11.03% |
| Dec 31, 2018 | 15.77B | -21.26% |
| Dec 29, 2017 | 20.02B | 16.36% |
| Dec 30, 2016 | 17.21B | -19.30% |
| Dec 31, 2015 | 21.33B | 8.16% |
| Dec 31, 2014 | 19.72B | 21.91% |
| Dec 31, 2013 | 16.17B | 59.07% |
| Dec 31, 2012 | 10.17B | 5.83% |
| Dec 30, 2011 | 9.61B | 1.90% |
| Dec 31, 2010 | 9.43B | 25.55% |
| Dec 31, 2009 | 7.51B | 34.82% |
| Dec 31, 2008 | 5.57B | -26.08% |
| Dec 31, 2007 | 7.54B | -12.74% |
| Dec 29, 2006 | 8.64B | 0.04% |
| Dec 30, 2005 | 8.63B | 39.95% |
| Dec 31, 2004 | 6.17B | -2.03% |
| Dec 31, 2003 | 6.30B | 8.40% |
| Dec 31, 2002 | 5.81B | -11.90% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 967.33B |
| Johnson & Johnson | 499.57B |
| AbbVie | 405.28B |
| UnitedHealth Group | 304.72B |
| AstraZeneca | 284.35B |
| Novartis AG | 266.00B |
| Merck & Co. | 264.21B |
| Novo Nordisk | 230.76B |